NeurologyLive Friday 5 — July 31, 2020
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 31, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: AAIC 2020: Nilotinib Has Safe and Tolerable Profile in Alzheimer Disease
Results presented virtually by Raymond Scott Turner, MD, PhD, support a larger, multi-center, phase 3 study to determine the safety and efficacy of nilotinib in patients with Alzheimer disease.
2: Insights: Spectrum of SMA Phenotypes at Presentation
Tim Hagenacker, MD, describes spinal muscular atrophy as a very broad clinical spectrum disease, highlighting the various ways it can present in patients.
3: AAIC 2020: Influenza, Pneumonia Vaccination May Reduce Alzheimer Disease Risk
A trio of studies suggest that consistently vaccinations for influenza and pneumonia may reduce the incidence of Alzheimer later in life, as well as mortality for older adults.
4: Podcast: Trends in the Alzheimer Clinical Pipeline
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jeffrey Cummings, MD, ScD, who discusses a recent review he and colleagues did of the trends in the Alzheimer Disease pipeline and what he expects for the future of the disease's care.
5: Ped-MSSS May Serve as Alternative to EDSS in Pediatric-Onset MS
The findings indicate that the use of a MS severity score (Ped-MSSS) model may provide an alternative to EDSS scoring, which has been shown to be lower in pediatric disease, in clinical assessment of disease severity and disability accrual.
